trending Market Intelligence /marketintelligence/en/news-insights/trending/mhxzjyivv-mv7ewug0asta2 content esgSubNav
In This List

Mylan to launch 2 HIV combination treatments in US

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Mylan to launch 2 HIV combination treatments in US

Mylan NV is launching two new HIV combination treatments approved by the U.S. Food and Drug Administration in February.

Symfi Lo will be launched in the U.S. in the coming weeks, followed by Cimduo in the second quarter of 2018.

According to Mylan, Symfi Lo is a single-tablet regimen combination of efavirenz, lamivudine and tenofovir disoproxil fumarate. It is approved to treat HIV-1 in children and adult patients who weigh at least 35 kilograms.

Cimduo is a combination of lamivudine and tenofovir disoproxil fumarate. The drug is recommended for use in combination with other antiretroviral agents to treat HIV-1 children and adult patients who weigh at least 35 kilograms.

The pharmaceutical company said the two medicines will be available at a significantly discounted price compared to the wholesale cost of other single-tablet regimen and tenofovir-based double combination products now available on the U.S. market.